ImmunoGen, Inc. (IMGN) |
|
3.96 -0.12 (-2.94%)
|
03-17 16:00 |
|
Open: |
4.08 |
Pre. Close: |
4.08 |
|
High:
|
4.1 |
Low:
|
3.855 |
|
Volume:
|
4,703,788 |
Market Cap:
|
895(M) |
|
|
|
Technical analysis |
as of: 2023-03-20 7:46:47 AM |
|
Overall:
|
  |
| Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected. |
| Target: |
Six months: 4.91 One year: 5.3 |
| Support: |
Support1: 3.66 Support2: 3.04 |
| Resistance: |
Resistance1: 4.2 Resistance2: 4.53 |
| Pivot: |
4.07  |
| Moving Average: |
MA(5): 4.06 MA(20): 4.04
MA(100): 4.8 MA(250): 4.86 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.2 |
| Stochastic oscillator: |
%K(14,3): 43.9 %D(3): 48.2 |
| RSI: |
RSI(14): 44.1 |
| 52-week: |
High: 6.63 Low: 3.09 |
| Average Vol(K): |
3-Month: 3,533 (K) 10-Days: 3,336 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ IMGN ] has closed above bottom band by 33.6%. Bollinger Bands are 15.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
4.11 - 4.13 |
4.13 - 4.15 |
|
Low:
|
3.8 - 3.83 |
3.83 - 3.85 |
|
Close:
|
3.92 - 3.97 |
3.97 - 4 |
|
Company Description |
|
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts. |
Headline News |
Fri, 17 Mar 2023
Research Analysts Set Expectations for ImmunoGen, Inc.'s FY2025 ... - MarketBeat
Tue, 14 Mar 2023
Analysts Consensus Recommendation Is "Hold" for ImmunoGen, Inc ... - Best Stocks
Tue, 14 Mar 2023
Analyzing the Price-to-Earnings Ratio of ImmunoGen Inc. (IMGN) - The News Heater
Tue, 07 Mar 2023
ImmunoGen, Inc. (NASDAQ:IMGN) is expected to earn ($0.24) per ... - Best Stocks
Mon, 06 Mar 2023
ImmunoGen, Inc. (NASDAQ:IMGN) Expected to Earn Q1 2023 ... - MarketBeat
Sat, 04 Mar 2023
ImmunoGen, Inc. (NASDAQ:IMGN) to Post FY2025 Earnings of ... - MarketBeat
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
226 (M) |
| Shares Float |
203 (M) |
|
% Held by Insiders
|
0.4 (%) |
|
% Held by Institutions
|
93 (%) |
|
Shares Short
|
22,800 (K) |
|
Shares Short P.Month
|
17,780 (K) |
Stock Financials |
|
EPS
|
-0.84 |
|
EPS Est Next Qtl
|
-0.24 |
|
EPS Est This Year
|
-0.73 |
|
EPS Est Next Year
|
-1.38 |
|
Book Value (p.s.)
|
0.68 |
|
Profit Margin (%)
|
-205 |
|
Operating Margin (%)
|
-203.1 |
|
Return on Assets (ttm)
|
-31.6 |
|
Return on Equity (ttm)
|
-92.7 |
|
Qtrly Rev. Growth
|
47 |
|
Gross Profit (p.s.)
|
-0.47 |
|
Sales Per Share
|
0.48 |
|
EBITDA (p.s.)
|
-0.97 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-230 (M) |
|
Levered Free Cash Flow
|
-102 (M) |
Stock Valuations |
|
PE Ratio
|
-4.72 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
5.73 |
|
Price to Sales
|
8.22 |
|
Price to Cash Flow
|
-3.9 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
